Drug-induced maculopathy

International Ophthalmology Clinics

Volumn 39, Issue 4, 1999, Pages 67-82

  Kempen, John H ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIMALARIAL AGENT; CANTHAXANTHIN; CHLOROQUINE; CISPLATIN; CLOFAZIMINE; DEFEROXAMINE; DIGOXIN; HYDROXYCHLOROQUINE; INDOMETACIN; INTERFERON; ISOTRETINOIN; METHOXYFLURANE; NICOTINIC ACID; PHENOTHIAZINE DERIVATIVE; RETINOL DERIVATIVE; TAMOXIFEN;

CENTRAL SEROUS RETINOPATHY; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; EYE TOXICITY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULOPATHY; REVIEW; VISUAL IMPAIRMENT;

EID: 0032701627     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004397-199903940-00007     Document Type: Review

References (71)

1. Popert AJ. Chloroquine: a review. Rheumatol Rehab 1976;15:235-8
2. Hobbs H, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478
3. Bernstein HN. Ophthalmologic considerations and testing in patients receiving long-term antimalarial therapy. Am J Med 1983;75(1A):25-34
4. Mackenzie AH. An appraisal of chloroquine. Arthritis Rheum 1970;13:280-2291
5. Rynes RI. Ophthalmologic safety of long-term hydroxychloroquine sulfate treatement. Am J Med 1983;75(1A):35-39
6. Falcone PM, Paolini L, Lou PL. Hydroxychloroquine toxicity despite normal dose therapy. Arch Ophthalmol 1993;25(10):384-388
7. Legros J, Rosner I. Modifications electroretinographiques apres administration chronique de fortes does d'hydroxychloroquine et de desethylhydroxychloroquine chez le rat albinos. Arch Ophthalmol (Paris) 1971;31:165-180
8. MacKenzie AH. Pharmacologic actions of 4-aminoquinoline compounds. Am J Med 1983;75(1A):5-10
9. Rosenthal RA, Kolb H, Bergsma D, et al. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17:1158
10. Craythorn JM, Swartz M, Creel DJ. Clofazimine-induced bull's-eye retinopathy. Retina 1986;6(1):50-52
11. Cunningham CA, Friedberg DN, Carr RE. Clofazamine-induced generalized retinal degeneration. Retina 1990;10(2):131-134
12. Kaur I, Ram J, Kumar B, Kaur S, Sharma VK. Effect of clofazimine on the eye in multibacillary leprosy. Indian J Lepr 1990;62(1):87-90
13. Potts AM. Drug-induced macular disease. Trans Am Acad Ophthalmol Otolaryngol 1966;70:1054-1057
14. Potts AM. The concentration of phenothiazines in the eye of experimental animals. Invest Ophthalmol Vis Sci 1962;1(4):522-530
15. Marmor MF. Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol 1990;74:739-742
16. Tenebein M. Benefits of parenteral deferoxamine for acute iron poisoning. J Toxicol Clin Toxicol 1996;34(5):485-489
17. Gehlbach PL, Purple RL, Hallaway, PE, Hedlund BE. Polymer conjugation reduces deferoxamine induced retinopathy in an albino rat model. Invest Ophthalmol Vis Sci 1993;34(10):2871-2877
18. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy. Ophthalmology 1984;91(5): 443-451
19. Burns CA. Indomethacin, reduced retinal sensitivity and corneal deposits. Am J Ophthalmol 1968;66:825-835
20. Carr RE, Sigel IM. Retinal function in patients treated with indomethacin. Am J Ophthalmol 1973;75:302-306
21. Ibanez HE, Williams DF, Boniuk I. Crystalline retinopathy associated with long-term nitrofurantoin therapy. Arch Ophthalmol 1994;112:304-305
22. Albert DM, Bullock JD, Lahav M, Caine R. Flecked retina secondary to oxalate crystals from methoxyflurane anesthesia: clinical and experimental studies. Trans Am Acad Ophthalmol Otolaryngol 1975;79:817-826
23. Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978;3:203-211
24. Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. J Clin Oncol 1996;14 (3): 1018-1026
25. Longstaff S, Sigurdsson H, O'Keefe M, et al. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. Eur J Cancer Clin Oncol 1989;25:1805-1808
26. Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tomxifen treatment for breast cancer. Eye 1997;11:295-297
27. Heier JS, Dragoo RA, Enzenauer RW, et al. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117:772-775
28. Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 1992;69:2961-2964
29. Harnois C, Samson J, Malenfant M, Rousseau A. Canthaxanthin retinopathy: anatomic and functional reversibility. Arch Ophthalmol 1989;107:538-540
30. Leyon H, Ros AM, Nyberg S, Algvere P. Reversibility of canthaxanthin deposits within the retina. Acta Ophthalmol (Copenh) 1990;68(5):607-611
31. Goralczyk R, Buser S, Bausch J, et al. Occurrence of birefringent retinal inclusions in cynomolgus monkeys after high doses of canthaxanthin. Invest Ophthalmol Vis Sci 1997;38(3):741-752
32. Daicker B, Schiedt K, Adnet JJ, Bermond P. Canthaxanthin retinopathy. An investigation by light and electron microscopy and physicochemical analysis. Graefes Arch Clin Exp Ophthalmol 1987;225(3):189-197
33. Withering W. An account of the foxglove and some of its medical uses. Birmingham: M. Swinney, 1785
34. Haustein K-O, Oltmanns G, Rietbrock N, Alken RG. Differences in color vision impairment caused by digoxin, digitoxin, or pengitoxin. J Cardiovasc Pharmacol 1982;4(4): 536-541
35. Madreperla SA, Johnson MA, Nakatani K. Electrophysiologic and eletroretinographic evidence for photoreceptor dysfunction as a toxic effect of digoxin. Arch Ophthalmol 1994;112(6):807-812.
36. Weleber RG, Denman WT, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986;104:831-837
37. Lerman S. Ocular side effects of accutane therapy. Lens Eye Toxic Res 1992;9(3-4): 429-438
38. Brown RD, Grattan CEH. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989;73:286-288
39. Kaiser-Kupfer MI, Peck GL, Caruso RC, et al. Abnormal retinal function associated with fenretinide, an synthetic retinoid. Arch Ophthalmol 1986;104:69-70
40. Wilding G, Caruso R, Lawrence TS, et al. Retinal toxicity after high-dose cisplatin therapy. J Clin Oncol 1985;3(12):1683-1689
41. Burke E, Teeling M, Carney D, Eustace P. The retinotoxic effects of oncological agents. Bull Soc Belge Ophthalmol 1987;224:77-79
42. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol 1968;79:552-562
43. Mackool RJ, Muldoon T, Fortier A, Nelson D. Epinephrine-induced cystoid macular edema in aphakic eyes. Arch Ophthalmol 1977;95(5):791-793
44. Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol 1982;94(5):682
45. Ayyala RS, Cruz DA, Margo CE, et al. Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes. Am J Ophthalmol 1998;126(4):602-604
46. Callanan D, Fellman RL, Savage JA. Latanoprost-associated cystoid macular edema. Am J Ophthalmol 1998;126(1):134-135
47. Warwar RD, Bullock JD, Ballal D. Cyostoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105(2):263-268
48. Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology 1988;95(7):930-936
49. Fraunfelder FW, Fraunfelder FT, Illingworth DR. Adverse ocular effects associated with niacin therapy. Br J Ophthalmol 1995;79:54-56
50. Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol 1973;76(4):500-510
51. Bouzas EA, Scott MH, Mastorakos G. Central serous chorioretinopathy in endogenous hypercortisolism. Arch Ophthalmol 1993;111:1229-1233
52. Wakakura M, Ishikawa S. An evaluation of corticosteroid treatment for central serous chorioretinopathy. Rinsho Ganka 1980;34:123-129
53. Haimovici R, Gragoudas ES, Duker JS, et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology 1997;104(10):1653-1660
54. Karavellas MP, Lowder CY, Macdonald C, et al. Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. Arch Ophthalmol 1998;116(2):169-175
55. Zegans ME, Walton RC, Holland GN, et al. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol 1998;125(3):292-300
56. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis 1999;179(3):697-700
57. Maguire AM, Nichols CW, Crooks CW. Visual loss in cytomegalovirus retinitis caused by cystoid macular edema in patients without the acquired immune deficiency syndrome. Ophthalmology 1996;103:601-605
58. Conway BP, Campochiaro PA. Macular infarction after endophthalmitis treated with vitrectomy and intravitreal gentamicin. Arch Ophthalmol 1986;104:367-371
59. Campochiaro PA, Conway BP. Aminoglycoside toxicity - a survey of retinal specialists: implications for ocular use. Arch Ophthalmol 1991;109:946-950
60. Campochiaro PA, Lim JI. Aminoglycoside toxicity in the treatment of endophthalmitis. The Aminoglycoside Toxicity Study Group Arch Ophthalmol 1994;112(1):48-53
61. Millay RH, Klein ML, Shults WT, et al. Maculopathy associated with combination chemotherapy and osmotic opening of the blood-brain barrier
62. Kupersmith MJ, Frohman LP, Choi IS, et al. Visual system toxicity following intra-afterial chemotherapy. Neurology 1988;38(2):284-289
63. Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350-356
64. Chambers RB, Downie A, Foote B, Davidorf FH. Interferon alfa-associated retinopathy. J Am Osteopath Assoc 1997;97(1):43-45
65. Kawano T, Shigohira M, Uto H, et al. Retinal complications during interferon therapy for chronic hepatitis C. Am J Gastroenterol 1996;91(2):309-313
66. Sugano S, Suzuki T, Watanabe M, et al. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998;92(12):2441-2444
67. Chuman T, Nao-i N, Sawada A, et al. Interferon-innduced retinal changes. Nippon Ganka Gakkai Zasshi 1994;98(6):616-621
68. Soushi S, Kobayashi F, Obazawa H, et al. Evaluation of risk factors of interferon-associated retinopathy in patients with type C chronic active hepatitis. Nippon Ganka Gakkai Zasshi 1996;100(1):69-76
69. Sugano S, Yanagimoto M, Suzuki T, et al. Retinal complications with elevated circulating plasma C5a associated with interferon-alpha therapy for chronic active hepatitis C. Am J Gastroenterol 1994;89(11):2054-2056
70. Nishiwaki H, Ogura Y, Miyamoto K, et al. Interferon alfa induces leukocyte capillary trapping in rat retinal microcirculation. Arch Ophthalmol 1996;114:726-730
71. Abe T, Nakajima A, Satoh H, et al. Clinical characteristics of hepatitis C virus-associated retinopathy. Jpn J Ophthalmol 1995;39:411-419